The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -7,585,692 | -11,165,091 |
| Stock-based compensation | 470,471 | 1,400,608 |
| Depreciation | 96,986 | 96,647 |
| Amortization of right of use asset | 37,869 | 42,368 |
| Tax receivable | -21,564 | -2,025,564 |
| Prepaid expenses and other current assets | -50,572 | 145,953 |
| Other assets | - | 0 |
| Accounts payable and accrued expenses | 1,035,121 | 782,904 |
| Operating lease liability | -32,667 | -31,968 |
| Net cash used in operating activities | -5,905,776 | -6,994,921 |
| Purchase of property and equipment | 372,456 | 195,343 |
| Net cash used in investing activities | -372,456 | -195,343 |
| Payments of deferred offering costs | 166,755 | - |
| Proceeds from sale of common stock, net of offering costs | 10,774,386 | 1,104,292 |
| Proceeds from exercise of stock options | 516 | 5,824 |
| Net cash provided by financing activities | 10,608,147 | 1,110,116 |
| Effect of foreign currency on cash | -20,552 | 36,139 |
| Net change in cash and cash equivalents | 4,309,363 | -6,044,009 |
| Cash and cash equivalents at beginning of period | 17,681,954 | - |
| Cash and cash equivalents at end of period | 15,947,308 | - |
Immix Biopharma, Inc. (IMMX)
Immix Biopharma, Inc. (IMMX)